articleCirculationNov 17, 2014BRONZE OA

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

MPMilton PackerJJJohn J.V. McMurrayASAkshay S. DesaiJGJianjian GongMLMartin Lefkowitz

British Heart Foundation · Universidade de Santiago de Compostela · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. METHODS AND RESULTS: We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for…

Citation impact

665
total citations
FWCI
50.23
Percentile
100%
References
47
Citations per year

Authors

52

Topics & keywords

Topics
Keywords
  • Medicine
  • Enalapril
  • Heart failure
  • Neprilysin
  • Cardiology
  • Internal medicine
  • Angiotensin II
  • Angiotensin receptor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding